Jingnan Zhang¹, Junyi Wan¹, Yihang Li², Yu Han², Jiahua Pan³, Fang Fang¹, Shiliang Jiang⁴, Xiangbin Pan¹, Gejun Zhang^1,*

Congenital Heart Disease, Vol.18, No.2, pp. 219-234, 2023, DOI:10.32604/chd.2023.027562

Abstract Background: The Venus-P valve was the first self-expanding valve used world-wide for transcatheter pulmonary valve replacement (TPVR) in patients with severe pulmonary regurgitation (PR). We intended to report the extended follow-up results from the prospective trial (No. NCT02590679). Methods: A total of 38 patients with severe PR (mean age 24.2 ± 13.2) were included. Follow-up data were obtained after implanted at 1, 6, and 12 months and yearly after. The frame geometry was assessed on post-implant computer tomography (CT) scanning by calculating the non-circularity [circularity ratio (minimum diameter/maximum diameter) < 0.9] and under-expansion [expansion ratio (derived external valve area/nominal external valve area)… More > Graphic Abstract

R. Allen Ligon^1,*, Larry A. Latson¹, Mark M. Ruzmetov², Kak-Chen Chan¹, Todd Roth¹, Immanuel I. Turner², Frank G. Scholl², Steve Bibevski²

Congenital Heart Disease, Vol.16, No.3, pp. 285-297, 2021, DOI:10.32604/CHD.2021.014373

Abstract Background: Pulmonary valve replacement (PVR) can be accomplished via surgical, transcatheter, or hybrid approaches. There are inherent advantages to transcatheter PVR and hybrid PVR without cardiopulmonary bypass. We review the methods and results of a standardized institutional approach to PVR. Methods: Retrospective review of all PVR cases between February 2017 and February 2020. Hybrid PVR entailed off-pump RVOT plication with percutaneous transcatheter PVR. Results: Primary transcatheter PVR was attempted in 37, hybrid PVR was performed in 11, and on-pump surgical PVR was performed in 9. Median age at PVR was 27 years (6–65). Primary transcatheter PVR was successful in 35/37… More >